Hookipa Stock Story

Given the investment horizon of 60 days Hookipa Pharma is expected to generate 7.56 times more return on investment than the market. However, the company is 7.56 times more volatile than its market benchmark. It trades about 0.05 of its potential returns per unit of risk. The DOW is currently generating roughly -0.1 per unit of risk. As many adventurous traders are excited about healthcare space, it is only fair to examine the risk of shorting Hookipa Pharma based on its current volatility spike. We will go over odds for Hookipa Pharma to generate above-average margins next month. The recent Hookipa risk factors may impact the value of the stock as we estimate Hookipa Pharma as currently undervalued. The real value is approaching 4.42 per share.
Published over three months ago
View all stories for Hookipa Pharma | View All Stories

Should you take in more of Hookipa (NASDAQ:HOOK) based on recent volatility?

Hookipa Pharma currently holds roughly 82.27 M in cash with (64.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.75, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
On a scale of 0 to 100, Hookipa Pharma holds a performance score of 3. The company retains a Market Volatility (i.e., Beta) of 1.1918, which attests to a somewhat significant risk relative to the market. Let's try to break down what Hookipa's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Hookipa Pharma will likely underperform. Although it is vital to follow Hookipa Pharma current price history, it is good to be conservative about what you can do with the information regarding equity current price movements. The philosophy towards determining future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By evaluating Hookipa Pharma technical indicators, you can presently evaluate if the expected return of 0.44% will be sustainable into the future. Please utilizes Hookipa Pharma maximum drawdown, as well as the relationship between the expected short fall and rate of daily change to make a quick decision on whether Hookipa Pharma current trending patterns will revert.

How important is Hookipa Pharma's Liquidity

Hookipa Pharma financial leverage refers to using borrowed capital as a funding source to finance Hookipa Pharma ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Hookipa Pharma financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Hookipa Pharma's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Hookipa Pharma, but it might be worth checking our own buy vs. sell analysis

A Deeper look at Hookipa

The recent price surge of Hookipa Pharma may raise some interest from traders. The stock closed today at a share price of 1.37 on 382,000 in trading volume. The company executives may have good odds in positioning the firm resources to exploit market volatility in June. The stock standard deviation of daily returns for 90 days investing horizon is currently 9.78. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Hookipa Pharma partners.

Our take on Hookipa Pharma small plunge

Recent maximum drawdown is at 75.11. Hookipa Pharma is displaying above-average volatility over the selected time horizon. Investors should scrutinize Hookipa Pharma independently to ensure intended market timing strategies are aligned with expectations about Hookipa Pharma volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Hookipa Pharma's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Hookipa Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Hookipa Pharma Implied Volatility

Hookipa Pharma's implied volatility exposes the market's sentiment of Hookipa Pharma stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Hookipa Pharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Hookipa Pharma stock will not fluctuate a lot when Hookipa Pharma's options are near their expiration.

Our Takeaway on Hookipa Pharma Investment

Although some firms in the biotechnology industry are either recovering or due for a correction, Hookipa Pharma may not be performing as strong as the other in terms of long-term growth potentials. To conclude, as of the 16th of May 2022, our research shows that Hookipa Pharma is a rather very risky investment opportunity with a below average probability of financial unrest in the next two years. From a slightly different view, the entity currently appears to be undervalued. Our up-to-date 90 days buy-or-sell advice on the firm is Strong Hold.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Hookipa Pharma. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com